XBiotech Inc. — Q1 2017 Form 10-Q
Business context and reporting period
For the three months ended March 31, 2017, XBiotech was a pre-commercial biopharmaceutical company developing naturally occurring “True Human” monoclonal antibodies. Its lead candidate, Xilonix, was being developed for colorectal cancer. The financial statements are unaudited and prepared under U.S. GAAP.
Financial performance and liquidity
| Metric | Q1 2017 | Q1 2016 / comparator |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $8.2 million | $7.8 million |
| General and administrative expense | $2.1 million | $2.4 million |
| Total operating expenses / operating loss | $10.3 million / $(10.3) million | $10.2 million / $(10.2) million |
| Net loss | $(10.6) million | $(10.3) million |
| Net loss per share, basic and diluted | $(0.32) | $(0.32) |
| Cash and cash equivalents | $54.6 million at March 31 | $34.3 million at December 31, 2016 |
| Operating cash use | $11.9 million | $9.9 million |
| Investing cash use | $0.6 million | $2.9 million |
| Financing cash provided | $32.7 million | $0 |
No product revenue or profit was reported; margins are not meaningful for this pre-revenue company. Total assets were $87.6 million and total liabilities were $5.3 million at quarter-end. The filing reports no debt. Current assets of $57.1 million substantially exceeded current liabilities of $5.3 million. Cash increased by $20.3 million during the quarter, primarily due to equity issuance. The company reported an accumulated deficit of $194.0 million.
Material changes versus the prior comparable period
- Net loss increased by $0.3 million, while operating expenses were nearly flat. R&D rose 5%, reflecting higher laboratory and manufacturing supplies, personnel and facility costs; clinical trial and sponsored research expense declined.
- G&A decreased 14%, mainly because Q1 2016 included a larger charge for immediately vested director options. Professional fees increased, including costs related to European commercialization activities and corporate legal matters.
- Operating cash use increased by $2.0 million. Investing cash use declined as construction spending eased following completion of the new manufacturing facility.
- Equity financing raised approximately $32.6 million net from a private share sale and sales under the H.C. Wainwright agreement; employees also exercised options. Shares outstanding rose to 35.2 million at March 31 from 32.6 million at December 31, 2016.
Outlook, developments, and risks
- The EMA issued a negative “trend vote” after an oral explanation on Xilonix’s European marketing application. Management said a positive CHMP opinion at the May decision vote was unlikely and further steps would be needed to potentially obtain approval.
- Enrollment was complete in a second Phase III metastatic colorectal cancer study involving more than 600 patients. The first interim analysis was completed in February 2017; a second was planned for mid-June 2017.
- The company reported completion of its Phase I/II study of 514G3 for S. aureus bacteremia and announced topline results in April 2017. Its new 40,000-square-foot Austin manufacturing facility was completed in August 2016 and increased production capacity approximately tenfold.
- Management expected quarter-end cash to fund operating expenses and capital expenditures through the end of 2018, subject to assumptions that may prove incorrect. It expected continued substantial losses and noted that revenue depends on regulatory approval and successful commercialization.
- A prior-period error resulted in a $1.0 million overstatement of 2016 clinical trial expense and corresponding overaccrual at year-end. The company recorded the full adjustment in Q1 2017, reducing Q1 clinical trial expense; management considered the adjustment immaterial to both periods.
- A California securities class action concerning alleged IPO disclosures about the European Xilonix Phase III trial remained pending; a hearing was set for June 7, 2017. The related Texas action had been dismissed with prejudice. The company could not estimate the California case’s outcome or financial impact.
- Risk factors were reported as unchanged from the 2016 Form 10-K. Key stated risks include clinical and regulatory outcomes, commercialization, financing needs, competition, intellectual property, and the ability to achieve profitability. Management reported no material market-risk exposure and no hedging activity.
- After quarter-end, Senior Vice President of Operations Kelly Thornburg resigned effective May 5, 2017.
Important facts for investors to verify
- EMA and CHMP decisions, the additional steps required for possible Xilonix approval, and the status of any commercialization plans.
- Results and timing of the second interim analysis in the Phase III metastatic colorectal cancer study, including any regulatory or clinical consequences.
- Details and interpretation of 514G3 topline results and the next development steps.
- Cash burn, financing needs, and the assumptions supporting management’s estimate that cash would last through year-end 2018.
- The status, potential exposure, and any subsequent developments in the California securities class action.
- The $1.0 million clinical-trial accrual correction and its effect on comparisons of Q1 2017 expenses with prior periods.